Support Alert

Class 4 medicines defect information: Aspar Pharmaceuticals Limited, Ibuprofen 200mg and 400mg tablets packaged in various liveries

Aspar Pharmaceuticals Limited has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the Patient Information Leaflets (PILs) within various ibuprofen packs are missing some information identified from post-marketing experience that should be documented in Section 3 (How to take the tablets) and Section 4 (Possible side effects) of the PIL.

Further information including details of the affected products, what the PIL should say and advice for healthcare professionals can be found on the MHRA website.


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.